Armed with new Phase I data, Icannex Healthcare is now focusing on a Phase II trial of its cannabidiol (CBD) and hydroxychloroquine combo therapy in rheumatoid arthritis.
In new topline data from a Phase I study, Icannex’s combo was well-tolerated with no reported serious adverse events. The trial tested the combination, known as IHL-675A, compared to Jazz Pharmaceuticals’s Epidiolex (CBD) and Sanofi’s Plaquenil (hydroxychloroquine) in healthy volunteers. During the Phase I trial (ACTRN12622000289718p), the same number of treatment-emergent adverse events were reported for IHL-675A and Epidiolex.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
With the new Phase I data in hand, Icannex is now focused on an ongoing Phase II trial of IHL-675A in 120 patients with rheumatoid arthritis. Hydroxychloroquine is already approved and commonly used in rheumatoid arthritis. GlobalData predicts the rheumatoid arthritis market will exceed $21.4 billion by 2029.
As a primary endpoint, the Phase II trial uses the RAPID3 assessment, which measures function, pain, and patient global estimate of status.The study will include four arms: IHL-675A, CBD alone, hydroxychloroquine alone, and placebo.
Looking ahead, Icannex also said it is developing Phase II trial plans for IHL-675A in inflammatory bowel disease and lung inflammation.
CBD can reduce inflammation of damaged tissue, and hydroxychloroquine can reduce T cell activation and interfere with pro-inflammatory signaling. While the buzz surrounding CBD medications has surged, researchers are still gathering evidence of the compound’s properties and potential therapeutic effects.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
